ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -21 مورد

Hematopoietic cell transplantation in classic Hodgkin lymphoma

Hematopoietic cell transplantation in classic Hodgkin lymphoma
Authors:
Craig Moskowitz, MD
Alvaro J Alencar, MD
Section Editor:
Nelson J Chao, MD
Deputy Editor:
Alan G Rosmarin, MD
Literature review current through: Apr 2025. | This topic last updated: Jan 27, 2025.

INTRODUCTION — 

Hematopoietic cell transplantation (HCT) is an important component of treatment for relapsed and refractory (r/r) classic Hodgkin lymphoma (cHL).

This topic reviews HCT for r/r cHL in adults.

Related topics include:

●Management of r/r cHL (see "Treatment of relapsed or refractory classic Hodgkin lymphoma")

●Management of patients with r/r cHL who are not eligible for HCT (see "Treatment of relapsed or refractory classic Hodgkin lymphoma")

●Overviews of cHL treatment in adults and children (see "Overview of Hodgkin lymphoma in children and adolescents" and "Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma")

DEFINITIONS — 

HCT can be used to treat relapsed or refractory (r/r) cHL.

Key definitions include:

●Relapse – Relapse (recurrence) is the reappearance of HL at sites of prior disease and/or at new sites after achieving complete response (CR).

●Refractory – Refractory (resistant) disease is the failure to achieve CR with initial therapy (primary refractory) or after salvage therapy (secondary refractory).

●Salvage therapy – Salvage (rescue) chemotherapy is a treatment that minimizes the disease burden of r/r cHL prior to HCT, as discussed separately. (See "Treatment of relapsed or refractory classic Hodgkin lymphoma", section on 'Overview of management'.)

●Conditioning therapy – Preparative (conditioning) therapy is a systemic treatment that ablates residual cHL and permits bone marrow engraftment by autologous or allogeneic hematopoietic cells.

Preparative regimens can be myeloablative conditioning (MAC), nonmyeloablative (NMA) conditioning, or reduced-intensity conditioning (RIC) (table 1).

●Autologous HCT – Autologous HCT utilizes the patient's own hematopoietic cells (from peripheral blood or bone marrow) to rescue hematopoiesis after preparative therapy for HCT.

●Allogeneic HCT – Allogeneic HCT utilizes hematopoietic cells from another individual (eg, related donor, unrelated donor, or umbilical cord blood) for hematopoietic rescue.

GOAL OF TRANSPLANTATION IN cHL — 

The goal of HCT in relapsed or refractory (r/r) cHL is to achieve long-term disease control (ie, cure) when possible. For patients who do not achieve cure, HCT can prolong life, improve the quality of life, and/or alleviate symptoms.

Integration of HCT with other aspects of management of r/r HL is described separately. (See "Treatment of relapsed or refractory classic Hodgkin lymphoma".)

AUTOLOGOUS TRANSPLANTATION — 

Management of relapsed or refractory (r/r) cHL prior to autologous HCT (algorithm 1) is discussed separately. (See "Treatment of relapsed or refractory classic Hodgkin lymphoma".)

Our approach to management is consistent with guidelines of the American Society of Blood and Marrow Transplantation and the European Society for Blood and Marrow Transplantation [1,2].

Indications for autologous HCT — The indications for autologous HCT and its integration with other aspects of management of first relapse or primary refractory cHL in adults (algorithm 1) are discussed separately. (See "Treatment of relapsed or refractory classic Hodgkin lymphoma", section on 'Autologous HCT'.)As

Chemosensitivity of the tumor is critical for use of autologous HCT. Outcomes are superior when autologous transplantation is performed after a complete metabolic response by positron emission tomography (PET), but transplantation may be considered after a partial response, especially when immune checkpoint inhibitors are included as part of salvage programs. (See "Treatment of relapsed or refractory classic Hodgkin lymphoma", section on 'Autologous HCT'.)

Eligibility for autologous HCT — Eligibility for autologous HCT may vary among centers.

Our eligibility criteria for autologous HCT in r/r cHL include:

●Performance status – Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (table 2).

●Medical fitness – Adequate cardiac, pulmonary, kidney, and liver function, and appropriate psychosocial support.

●Age – Age limits for autologous HCT vary by institution and are not absolute, but some experts suggest autologous HCT for patients ≤70 or ≤75 years of age.

Eligibility and the risks and benefits of HCT must be discussed with the prospective patient and loved ones.

Additional discussion of eligibility for autologous HCT is provided separately. (See "Determining eligibility for autologous hematopoietic cell transplantation", section on 'Pretransplant evaluation'.)

Conditioning regimen — There is no consensus preparative (conditioning) regimen for autologous HCT in r/r cHL.

The choice of conditioning regimen is influenced by patient comorbidities, short- and long-term toxicities, and institutional preferences, as discussed separately. (See "Preparative regimens for hematopoietic cell transplantation".)

Acceptable options for preparative regimens (table 1) include:

●BEAM (BCNU [carmustine], etoposide, cytarabine, melphalan) is used by most centers.

●Acceptable alternative regimens include:

•CBV (cyclophosphamide, BCNU, etoposide)

•Bu/Cy (busulfan, cyclophosphamide)

•Bu/Mel (busulfan, melphalan)

Studies of preparative regimens for autologous HCT in cHL include:

●Compared with BEAM, alternative conditioning regimens (eg, CBV, Bu/Cy, total body radiation) were associated with higher mortality in a registry study of >1000 patients who underwent autologous HCT for cHL [3].

●Other retrospective studies reported that alternative conditioning regimens may be associated with better outcomes than BEAM but were more toxic [4,5].

Graft source — Apheresis-derived peripheral blood hematopoietic stem/progenitor cells are preferred because of faster engraftment, as discussed separately. (See "Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells".)

Consolidative radiation — To improve local control, we suggest consolidative involved-field radiation therapy (IFRT) for localized or bulky disease that was not previously radiated.

If it would entail significant radiation exposure to the bowels, care should be taken to exclude liver (to lessen the risk for hepatic sinusoidal obstruction syndrome [SOS]), lung (to avoid interstitial pneumonitis), and abdominal masses.

The timing of radiation therapy varies among centers; most centers administer IFRT after HCT, but it can also be given before HCT. No studies have compared outcomes with consolidative IFRT before versus after HCT.

A retrospective study reported no difference in overall survival (OS) but better disease-free survival (DFS) among 46 patients with relapsed cHL who received IFRT within two months of autologous HCT, compared with 46 matched patients who underwent autologous HCT without IFRT [6]. Other retrospective studies of autologous HCT report similar outcomes [6-11].

Maintenance therapy — Maintenance therapy may benefit certain patients after autologous HCT for r/r cHL.

Brentuximab vedotin — For brentuximab vedotin (BV)-naïve patients at higher risk of relapse after autologous HCT (described below), we suggest BV therapy based on improved progression-free survival (PFS).

There is no proven benefit for BV maintenance for patients at lower risk of relapse or who received BV as a component of initial treatment for cHL.

●Administration – We treat with BV 1.8 mg/kg (to a maximum dose of 180 mg) every 3 weeks beginning 30 to 45 days after HCT for up to 16 cycles. For patients who received BV as a component of salvage therapy, we treat with up to 10 cycles.

●Indications – At least one of the following high-risk features:

•Primary refractory cHL or relapse <12 months after initial therapy

•Less than complete response (CR) to most recent salvage therapy

•B symptoms at relapse

•Relapse with extranodal disease

•Two or more salvage therapies

We do not administer BV maintenance to patients who do not meet these high-risk criteria, are intolerant of BV, or have cHL progression while receiving BV.

For patients who received BV as a component of their first-line therapy for cHL, we limit BV maintenance to patients with high-risk criteria who relapsed >12 months after an initial response to BV.

●Adverse effects – Peripheral neuropathy is seen in more than one-half of patients treated with maintenance BV, but it improves or resolves in most after discontinuation; motor neuropathy and neutropenia are seen in one-quarter to one-third of patients.

●Outcomes

•In the multicenter AETHERA trial, 329 BV-naïve patients with high-risk features who underwent autologous HCT were randomly assigned to maintenance therapy with BV versus placebo [12]. Compared with placebo, BV was associated with superior five-year PFS (59 versus 41 percent; hazard ratio [HR] 0.52 [95% CI 0.38-0.72]) [13]. OS did not differ between the two arms of the trial, but the conclusions are limited by the large number of patients who crossed over from the placebo arm to BV after progression. BV was associated with more peripheral sensory neuropathy (56 versus 16 percent, respectively), peripheral motor neuropathy (23 versus 2 percent), and neutropenia (35 versus 12 percent). With a five-year follow-up, peripheral neuropathy improved in 90 percent and completely resolved in 73 percent.

•A study of 118 patients with high-risk features reported that only 14 percent received all planned doses; 72 percent of discontinuations were due to toxicity [14]. Two-year PFS did not differ when comparing patients who received >75 percent of all planned doses versus ≤50 percent of doses [14].

Other maintenance regimens — There is no proven benefit for other maintenance regimens, and we do not use them outside of a clinical trial.

A multicenter study with pembrolizumab 200 mg intravenously every 3 weeks for up to 8 cycles beginning within 21 days after autologous HCT hospital discharge reported 100 percent OS and 82 percent PFS after 18 months among 28 evaluable patients [15]. Toxicity included a grade 3 adverse effect in 30 percent of patients and a grade 2 immune-related adverse effect in 40 percent.

Tandem autologous HCT — There is no clear benefit for tandem (ie, sequential) autologous HCT for r/r cHL.

A matched cohort analysis of patients from two different studies reported that a single autologous HCT followed by BV maintenance was associated with better outcomes than tandem transplantation [16]. Other prospective studies demonstrated no clear benefits for tandem transplantation, even for patients with adverse prognostic features [17-20].

Prognostic factors for autologous HCT in cHL — Outcomes after autologous HCT are related to disease status prior to transplantation and response to salvage therapy.

Retrospective studies reported inferior outcomes with an incomplete metabolic response to salvage chemotherapy, B symptoms, shorter duration of remission (ie, <1 year), extranodal disease, ≥1 prior chemotherapy regimen, and poor performance status [21-42].

A prognostic model to predict PFS after HCT was developed based on the outcomes of 337 patients with r/r cHL who underwent autologous HCT. The prognostic model was validated in a separate cohort of 391 patients [27]. A multivariate model identified the following four major risk factors at the time of HCT with each factor assigned a relative weight:

●Poor performance status (Karnofsky performance score <90) (table 3) – 1 point

●Chemotherapy-resistant disease – 1 point

●>3 prior chemotherapy regimens – 2 points

●Extranodal disease – 2 points

Three risk groups were identified based on the sum of the total score: low risk (score 0), intermediate risk (score 1 to 3), and high risk (score 4 to 6); the four-year PFS rates for these groups were 71, 60, and 42 percent, respectively.

ALLOGENEIC TRANSPLANTATION — 

Management of multiply relapsed or refractory (r/r) cHL prior to allogeneic HCT is discussed separately. (See "Treatment of relapsed or refractory classic Hodgkin lymphoma".)

Indications for allogeneic HCT — Allogeneic HCT is generally limited to medically eligible patients who relapse after brentuximab vedotin (BV) and autologous HCT and had only a partial response or progressive disease after immune checkpoint inhibition (ICI). We generally do not proceed with allogeneic HCT for patients who had a complete response (CR) with ICI.

In settings where ICI is not available, allogeneic HCT may be considered for patients with r/r cHL after autologous HCT.

Allogeneic HCT in patients who were previously treated with ICI may be associated with an increased risk for acute graft-versus-host disease (GVHD), hyperacute GVHD, chronic GVHD, hepatic sinusoidal obstructive syndrome (SOS) after reduced-intensity conditioning (RIC), and glucocorticoid-requiring febrile syndrome.

Post-transplant cyclophosphamide can be considered for GVHD prophylaxis in this setting [43].

Eligibility for allogeneic HCT — Age, medical fitness, and risk category inform eligibility for allogeneic HCT in r/r cHL, but criteria vary between institutions.

Our approach follows:

●Risk category – Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) is a useful tool for assessing risk prior to allogeneic HCT [44].

There is no HCT-CI score that we consider an absolute exclusion to allogeneic HCT, but outcomes are less favorable for patients with an HCT-CI score ≥5; we discuss the higher risk and lower expectations of allogeneic HCT in this setting with the patient and loved ones.

●Medical fitness – Medical fitness for allogeneic HCT is discussed separately. (See "Allogeneic hematopoietic cell transplantation: Indications, eligibility, and prognosis".)

●Age – Most institutions restrict RIC/nonmyeloablative (NMA) HCT to patients ≤70 years old. For institutions that offer myeloablative conditioning (MAC) HCT in this setting, allogeneic HCT is typically limited to patients ≤60 years old.

Allogeneic donor source — We favor related-donor allogeneic hematopoietic cells for allogeneic HCT for r/r cHL, when available.

Details of donor selection for allogeneic HCT are provided separately. (See "Donor selection for hematopoietic cell transplantation".)

A systematic review concluded that all donor sources, including related, unrelated, and haploidentical donors, and umbilical cord blood were reasonable options for allogeneic HCT in patients with cHL [45]. Other studies have reported similar conclusions [46,47].

Bridging therapy — There should be adequate disease control prior to transplant.

C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) or another alkylator-based chemotherapy can be used as bridging therapy to achieve disease control.

ICI therapy appears to resensitize cHL to cytotoxic therapy, reinforcing its use in this setting [48,49].

Allogeneic HCT conditioning — RIC or NMA preparative regimens are preferred for allogeneic HCT in r/r cHL. Some institutions offer MAC HCT in this setting.

RIC and NMA preparative regimens (table 1) provide graft-versus-lymphoma effects with less toxicity than myeloablative regimens. The selection of RIC versus NMA conditioning is based on institutional preferences and is discussed separately. (See "Preparative regimens for hematopoietic cell transplantation", section on 'NMA and RIC regimens'.)

Our preferred RIC regimen is fludarabine and melphalan [46,50-52]; some centers add alemtuzumab to this regimen [53,54].

RIC/NMA conditioning offers a survival advantage compared with MAC for allogeneic HCT in r/r cHL. As an example, a retrospective analysis of 168 patients reported that, compared with MAC HCT, RIC was associated with improved overall survival (OS; hazard ratio [HR] 2.1 [95% CI 1.3-3.3]) and lower nonrelapse mortality (NRM; HR 2.9 [95% CI 1.6-5.0]) despite an increased risk of relapse or progression [55]. Another retrospective comparison of 312 patients reported no significant difference in OS, event-free survival (EFS), relapse rate, or NRM between MAC versus RIC allogeneic HCT [56].

Informative studies regarding RIC/NMA conditioning allogeneic HCT for r/r cHL include:

●A prospective study of 78 patients reported 71 and 43 percent one-year and four-year OS, respectively, and 48 and 24 percent one-year and four-year PFS [57]. One-year NRM was 15 percent.

●Retrospective analysis of 191 patients who underwent RIC regimens reported three-year rates of OS, PFS, relapse, and NRM were 63, 39, 46, and 16 percent, respectively [58].

●A retrospective study of 143 patients reported 50 and 30 percent one-year OS and PFS, respectively, and 37 and 20 percent two-year OS and PFS [59]. Rates of treatment-related mortality at 100 days and two years were 15 and 33 percent, respectively.

Post-HCT management — Following allogeneic HCT, we offer radiation therapy to localized or bulky disease that was not previously radiated, and we offer maintenance BV therapy to BV-naïve patients, as described above. (See 'Consolidative radiation' above and 'Maintenance therapy' above.)

Management of GVHD is discussed separately. (See "Treatment of acute graft-versus-host disease".)

Surveillance after allogeneic HCT is discussed below. (See 'Post-HCT surveillance' below.)

Prognostic factors for allogeneic HCT — A systematic review and meta-analysis of 42 studies reported that achieving remission prior to allogeneic HCT was associated with improved OS at two years and improved relapse-free survival at one year [60].

POST-HCT SURVEILLANCE — 

Patients are seen at periodic intervals to monitor disease status.

Transplant recipients are at risk of developing therapy-related complications for years after treatment, as described separately. (See "Second malignancies after treatment of classic Hodgkin lymphoma" and "Long-term care of the adult hematopoietic cell transplantation survivor" and "Approach to the adult survivor of classic Hodgkin lymphoma".)

INFORMATION FOR PATIENTS — 

UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)

●Basics topics (see "Patient education: Autologous bone marrow transplant (The Basics)" and "Patient education: Allogeneic bone marrow transplant (The Basics)")

●Beyond the Basics topics (see "Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)" and "Patient education: Hodgkin lymphoma in adults (Beyond the Basics)")

SUMMARY AND RECOMMENDATIONS

●Description – Autologous hematopoietic cell transplantation (HCT) can cure more than one-half of adult patients with classic Hodgkin lymphoma (cHL) who relapse after initial complete response (CR) or fail to achieve initial CR (primary refractory cHL).

Allogeneic HCT has a limited role in relapsed or refractory (r/r) cHL.

●Goal of transplantation – The goal of HCT in r/r cHL is to achieve long-term disease control/cure, improve the quality of life, and/or alleviate symptoms. (See 'Goal of transplantation in cHL' above.)

●Autologous HCT

•Indications – Indications for HCT and integration with other aspects of management of r/r cHL are discussed separately. (See "Treatment of relapsed or refractory classic Hodgkin lymphoma".)

•Eligibility – Eligibility requires adequate organ function, performance status, and response to salvage therapy, as described above. (See 'Eligibility for autologous HCT' above.)

•Conditioning regimen – Most centers use BEAM (BCNU [carmustine], etoposide, cytarabine, melphalan) conditioning, but there are other acceptable options. (See 'Conditioning regimen' above.)

•Graft source – Apheresis-derived peripheral blood hematopoietic stem/progenitor cells are generally preferred. (See 'Graft source' above.)

•Post-HCT management

-Consolidative radiation therapy – We suggest post-HCT radiation therapy for localized or bulky disease that was not previously radiated, to improve local control (Grade 2C). (See 'Consolidative radiation' above.)

-Maintenance therapy – For brentuximab vedotin (BV)-naïve patients at higher risk of relapse after autologous HCT, we suggest BV maintenance therapy to prolong progression-free survival (Grade 2B).

Higher-risk features for relapse include ≥1 of the following: primary refractory cHL or relapse <12 months after initial therapy; less than CR to most recent salvage therapy; B symptoms at relapse; relapse with extranodal disease; and ≥2 salvage regimens.

There is no proven benefit for BV maintenance in patients without higher-risk features, who received BV as a component of initial treatment for cHL, who had disease progression while receiving BV, or who had BV intolerance.

●Allogeneic HCT – Allogeneic HCT is generally limited to medically eligible patients who relapse after BV and autologous HCT and have less than a CR with immune checkpoint inhibition. Eligibility, preferred conditioning regimens and donor source, and other aspects of allogeneic HCT for r/r cHL are discussed above. (See 'Allogeneic transplantation' above.)

ACKNOWLEDGMENTS — 

The UpToDate editorial staff acknowledges George P Canellos, MD, Peter M Mauch, MD, and Ginna G Laport, MD, who contributed to earlier versions of this topic review.

  1. Perales MA, Ceberio I, Armand P, et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015; 21:971.
  2. Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015; 50:1037.
  3. Chen YB, Lane AA, Logan BR, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015; 21:1046.
  4. Nieto Y, Popat U, Anderlini P, et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 2013; 19:410.
  5. Bains T, Chen AI, Lemieux A, et al. Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2014; 55:583.
  6. Kahn S, Flowers C, Xu Z, Esiashvili N. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma? Int J Radiat Oncol Biol Phys 2011; 81:175.
  7. Garfin PM, Link MP, Donaldson SS, et al. Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution. Biol Blood Marrow Transplant 2015; 21:326.
  8. Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012; 119:1665.
  9. Evens AM, Altman JK, Mittal BB, et al. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Ann Oncol 2007; 18:679.
  10. Rapoport AP, Meisenberg B, Sarkodee-Adoo C, et al. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 2002; 29:303.
  11. Wendland MM, Asch JD, Pulsipher MA, et al. The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J Clin Oncol 2006; 29:189.
  12. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385:1853.
  13. Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 2018; 132:2639.
  14. Wagner CB, Boucher K, Nedved A, et al. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica 2023; 108:3025.
  15. Armand P, Chen YB, Redd RA, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood 2019; 134:22.
  16. Marouf A, Molinari N, Sibon D, et al. Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA. Br J Haematol 2023; 202:379.
  17. Morschhauser F, Brice P, Fermé C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008; 26:5980.
  18. Sibon D, Morschhauser F, Resche-Rigon M, et al. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica 2016; 101:474.
  19. Fung HC, Stiff P, Schriber J, et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant 2007; 13:594.
  20. Smith EP, Hongli L, Friedberg JW, et al. SWOG S0410/BMT CTN 0703: A phase II trial of tandem autologous stem cell transplantation (AHCT) for patients with primary progressive or recurrent Hodgkin lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987). Blood 2014; :abstract 676.
  21. Sieniawski M, Franklin J, Nogova L, et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 2007; 25:2000.
  22. Popat U, Hosing C, Saliba RM, et al. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33:1015.
  23. Lavoie JC, Connors JM, Phillips GL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106:1473.
  24. Stiff PJ, Unger JM, Forman SJ, et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003; 9:529.
  25. Tarella C, Cuttica A, Vitolo U, et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer 2003; 97:2748.
  26. Constans M, Sureda A, Terol MJ, et al. Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. Ann Oncol 2003; 14:745.
  27. Hahn T, McCarthy PL, Carreras J, et al. Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma. Biol Blood Marrow Transplant 2013; 19:1740.
  28. Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005; 16:625.
  29. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12:1065.
  30. Greaves P, Wilson A, Matthews J, et al. Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention-to-treat analysis. Br J Haematol 2012; 157:201.
  31. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97:616.
  32. Martín A, Fernández-Jiménez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 2001; 113:161.
  33. Gutierrez-Delgado F, Holmberg L, Hooper H, et al. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant 2003; 32:279.
  34. Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005; 16:116.
  35. Wadehra N, Farag S, Bolwell B, et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant 2006; 12:1343.
  36. Perz JB, Giles C, Szydlo R, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant 2007; 39:41.
  37. Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007; 109:486.
  38. Bierman PJ, Lynch JC, Bociek RG, et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002; 13:1370.
  39. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002; 20:221.
  40. Martínez C, Salamero O, Arenillas L, et al. Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: long-term outcome of 61 patients from a single institution. Leuk Lymphoma 2007; 48:1968.
  41. Qazilbash MH, Devetten MP, Abraham J, et al. Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia. Acta Haematol 2003; 109:119.
  42. Smith SD, Moskowitz CH, Dean R, et al. Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. Br J Haematol 2011; 153:358.
  43. Merryman RW, Castagna L, Giordano L, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia 2021; 35:2672.
  44. Sorror ML. How I assess comorbidities before hematopoietic cell transplantation. Blood 2013; 121:2854.
  45. Messer M, Steinzen A, Vervölgyi E, et al. Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review. Leuk Lymphoma 2014; 55:296.
  46. Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008; 93:257.
  47. Robinson SP, Sureda A, Canals C, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009; 94:230.
  48. Stuver R, Noy A, Vardhana SA, et al. Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma. Br J Haematol 2024; 204:e17.
  49. Rossi C, Gilhodes J, Maerevoet M, et al. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers. Am J Hematol 2018.
  50. Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005; 35:943.
  51. Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006; 12:172.
  52. Chen R, Palmer JM, Popplewell L, et al. Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Ann Hematol 2011; 90:803.
  53. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365:1934.
  54. Peggs KS, Kayani I, Edwards N, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011; 29:971.
  55. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26:455.
  56. Genadieva-Stavrik S, Boumendil A, Dreger P, et al. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol 2016; 27:2251.
  57. Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012; 97:310.
  58. Marcais A, Porcher R, Robin M, et al. Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2013; 98:1467.
  59. Devetten MP, Hari PN, Carreras J, et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2009; 15:109.
  60. Rashidi A, Ebadi M, Cashen AF. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. Bone Marrow Transplant 2016; 51:521.
Topic 4760 Version 48.0

References

1 : Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation.

2 : Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.

3 : Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.

4 : Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.

5 : Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma.

6 : Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?

7 : Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution.

8 : Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.

9 : Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.

10 : Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy.

11 : The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease.

12 : Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

13 : Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.

14 : Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes.

15 : PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.

16 : Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.

17 : Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.

18 : Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.

19 : Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma.

20 : SWOG S0410/BMT CTN 0703: A phase II trial of tandem autologous stem cell transplantation (AHCT) for patients with primary progressive or recurrent Hodgkin lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987)

21 : Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.

22 : Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.

23 : High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.

24 : The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial.

25 : High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.

26 : Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome.

27 : Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.

28 : Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.

29 : Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.

30 : Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention-to-treat analysis.

31 : A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

32 : Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.

33 : Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen.

34 : Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).

35 : Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.

36 : LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.

37 : Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.

38 : The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation.

39 : New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.

40 : Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: long-term outcome of 61 patients from a single institution.

41 : Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia.

42 : Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres.

43 : Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.

44 : How I assess comorbidities before hematopoietic cell transplantation.

45 : Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review.

46 : Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.

47 : Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome.

48 : Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma.

49 : Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.

50 : Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.

51 : Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.

52 : Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma.

53 : Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.

54 : Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.

55 : Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

56 : Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

57 : Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

58 : Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).

59 : Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.

60 : Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis.